Study
| Prospective, multicenter, double-blinded, randomized phase 3 study |
| Previously untreated metastatic pancreatic adenocarcinoma |
| Nimotuzumab + Gemcitabine (n=41) vs. Gemcitabine (n=41) |
Efficacy
| mOS: 10.9 vs 8.5 mos, HR:0.66, p=0.080 |
| mPFS: 4.2 vs. 3.6 mos, HR:0.60, p=0.040 |
| mTTP: 4.7 vs. 3.7 mos, HR:0.67, p=0.311 |
| DCR: 68.3% vs. 63.4% |
Safety
| Grade≥ 3: Neutropenia (46%), hypertension (15%), dry skin, pruritus (13%), anemia (10%) |
J Clin Oncol AUG 30; 2023
http://doi.org/10.1200/JCO.22.02630
Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023
